Lineage Cell Therapeutics Inc. — Director's Dealing 2019

Mar 22, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2019-03-19

Reporting Person: Wirth Edward (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-19	Option to Purchase Common Shares	$1.57	A	350000	Acquired	2029-03-18	Common Shares (350000)	Direct

Footnotes

F1: One quarter of the options shall vest on March 18, 2020 and the remaining shall vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.